Literature DB >> 33817429

Globe salvage treatment in group D and group E retinoblastoma.

Ahmad Khaqan Hussain1, Rachwani Anil Rahul1, Rocha de Lossada Carlos2, Zamorano Martín Francisco3, García Lorente María3, Pennisi Flavia4, Bonzano Chiara5, Borroni Davide6.   

Abstract

Importance: Globe salvage marks the treatment success of retinoblastoma. Background: To evaluate four treatment strategies in group D and group E retinoblastoma. Design: Retrospective case series in a tertiary hospital. Participants: 81 patients with Group D and Group E retinoblastoma.
Methods: Participants were divided into four sets. In set I, eyes received primary intravenous chemotherapy (IVC), cryotherapy (CT), laser therapy (LT) and Intravitreal Chemotherapy with Melphalan (IViC). In set II, primary IVC was combined with second line IVC, CT, LT and IVT-M. Set III eyes received primary IVC and Intra-arterial chemotherapy (IAC), CT, LT and IViC. Set IV eyes received IAC, CT, LT and IViC. Treatment failure was defined as inadequate response during or after IVC or IAC. Main Outcome Measures: globe salvage and enucleation rates.
Results: 52 eyes were included in group D and 29 in group E. In group D, globe salvage was obtained in 8 out of 11 eyes in Set I, 13 out of 19 eyes in set II, 5 out 6 eyes in set III, and 13 out of 16 eyes in set IV. In group E, enucleation was performed in 17 eyes. Global salvage was obtained in 0 out of 2 eyes in set I, 2 out of 3 eyes in set II, 3 out of 5 in set III, and in 1 out of 2 eyes in set IV. Conclusions: IVC with adjuvant IAC, LT, CT and IViC has shown favorable results as a treatment method for group D and group E retinoblastoma. ©Romanian Society of Ophthalmology.

Entities:  

Keywords:  globe salvage; intravenous chemotherapy; intravitreal Melphalan; retinoblastoma

Year:  2021        PMID: 33817429      PMCID: PMC7995513          DOI: 10.22336/rjo.2021.5

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  33 in total

Review 1.  The adverse events of chemotherapy for retinoblastoma: what are they? Do we know?

Authors:  Allison E Rizzuti; Ira J Dunkel; David H Abramson
Journal:  Arch Ophthalmol       Date:  2008-06

2.  Chemoreduction in the initial management of intraocular retinoblastoma.

Authors:  C L Shields; P De Potter; B P Himelstein; J A Shields; A T Meadows; J M Maris
Journal:  Arch Ophthalmol       Date:  1996-11

3.  Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.

Authors:  Carol L Shields; Arman Mashayekhi; Jacqueline Cater; Abdallah Shelil; Steven Ness; Anna T Meadows; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2005-06

4.  The International Classification of Retinoblastoma predicts chemoreduction success.

Authors:  Carol L Shields; Arman Mashayekhi; Angela K Au; Craig Czyz; Ann Leahey; Anna T Meadows; Jerry A Shields
Journal:  Ophthalmology       Date:  2006-09-25       Impact factor: 12.079

5.  Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.

Authors:  Jesse L Berry; Rima Jubran; Jonathan W Kim; Kenneth Wong; Simon R Bababeygy; Hashem Almarzouki; Thomas C Lee; A Linn Murphree
Journal:  Pediatr Blood Cancer       Date:  2012-09-19       Impact factor: 3.167

6.  Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.

Authors:  Francis L Munier; Marie-Claire Gaillard; Aubin Balmer; Sameh Soliman; Gregory Podilsky; Alexandre P Moulin; Maja Beck-Popovic
Journal:  Br J Ophthalmol       Date:  2012-06-13       Impact factor: 4.638

7.  Clinical profile, management, and outcome of retinoblastoma in singapore.

Authors:  Fiona Pin Miao Lim; Shui Yen Soh; Jayant Venkatramani Iyer; Ah Moy Tan; Handa Swati; Boon Long Quah
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2012-12-18       Impact factor: 1.402

8.  Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation.

Authors:  Carol L Shields; Swathi Kaliki; Saad Al-Dahmash; Duangnate Rojanaporn; Ann Leahey; Gregory Griffin; Pascal Jabbour; Jerry A Shields
Journal:  Retina       Date:  2013 Nov-Dec       Impact factor: 4.256

9.  Chorioretinal scar growth after 810-nanometer laser treatment for retinoblastoma.

Authors:  Thomas C Lee; Sang-Woo Lee; Marc J Dinkin; Michael D Ober; Katherine L Beaverson; David H Abramson
Journal:  Ophthalmology       Date:  2004-05       Impact factor: 12.079

10.  Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma.

Authors:  David H Abramson; Anthony B Daniels; Brian P Marr; Jasmine H Francis; Scott E Brodie; Ira J Dunkel; Y Pierre Gobin
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

View more
  2 in total

1.  Less is more: new one-step intracameral chemotherapy technique.

Authors:  Davide Borroni; Chiara Bonzano; Rahul Rachwani-Anil; Carlos Rocha-de Lossada; Francisco Zamorano Martín; Maria Garcia-Lorente; Elisabetta Bonzano; Hussain Ahmad Khaqan
Journal:  Rom J Ophthalmol       Date:  2021 Jul-Sep

2.  Bilateral enucleation for retinoblastoma: A study of 14 patients.

Authors:  Khaleel Machakuri; Swathi Kaliki
Journal:  Oman J Ophthalmol       Date:  2022-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.